Axsome Therapeutics, Inc.

Johnson Fistel, World Renowned Law Firm, Begins Investigation of Axsome. Shareholders Encouraged to Submit Their Information

Axsome Therapeutics, Inc. (NASDAQ: AXSM)
Johnson Fistel, LLP is investigating potential claims on behalf of Axsome Therapeutics, Inc. (NASDAQ: AXSM) against certain of its officers and directors.

Recently a class action complaint was filed against Axsome. Plaintiff alleges that Defendants made materially false and misleading statements during the Class Period. Specifically, Plaintiff alleges that: (i) Axsome’s CMC practices were deficient with respect to AXS-07 and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA; (iv) the FDA was unlikely to approve the AXS-07 NDA; and (v) as a result, Axsome had overstated AXS-07’s regulatory and commercial prospects.

If you are interested in learning more about the investigation, please contact lead analyst Jim Baker ( at 619-814-4471. If emailing, please include a phone number. 

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.

Johnson Fistel, LLP
Jim Baker, 619-814-4471